Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms

As the field evolves, dual NK3/NK1 receptor antagonism—exemplified by elinzanetant—has emerged as a promising next step. This mechanism simultaneously modulates 2 pathways implicated in thermoregulation and stress response, potentially amplifying efficacy.

Panelists note that dual antagonism may improve mood, sleep, and other menopause-related symptoms, reflecting NK1’s role in broader neurochemical signaling. This multi-receptor strategy may also enhance treatment durability and address the emotional burden that often accompanies VMS.

The discussion suggests that dual antagonism could represent the next generation of menopause care, balancing symptom relief with holistic improvements in quality of life.